| P50 | author | Federico Piacentini | Q37839869 |
| | Pierfranco Conte | Q56798835 |
| | A Musolino | Q57076640 |
| | Maria Vittoria Dieci | Q57656975 |
| | Valentina Guarneri | Q58283362 |
| P2093 | author name string | A Ardizzoni | |
| | L Gianni | |
| | D G Generali | |
| | G Bisagni | |
| | S Sarti | |
| | M Ambroggi | |
| | D Boggiani | |
| | A Rimanti | |
| | K Cagossi | |
| | N Naldi | |
| | P Sgargi | |
| | D Zanoni | |
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 |
| | Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | Q27851763 |
| | Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831 | Q27853035 |
| | Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 |
| | Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial | Q30758991 |
| | Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. | Q30857631 |
| | Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 |
| | Evaluation of survival data and two new rank order statistics arising in its consideration | Q34054360 |
| | Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype | Q34434169 |
| | Mendelian proportions in a mixed population | Q34675746 |
| | Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. | Q35102480 |
| | Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. | Q35437978 |
| | Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | Q36064908 |
| | Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 |
| | Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients | Q37292031 |
| | Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study | Q37600494 |
| | Biology and clinical relevance of human natural killer cells | Q38015046 |
| | Biomarkers of drugs targeting HER-family signalling in cancer. | Q38150774 |
| | Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells | Q38346529 |
| | Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial | Q38407917 |
| | Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers | Q38717028 |
| | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. | Q39130461 |
| | Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. | Q39214969 |
| | Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Q39908130 |
| | Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 |
| | HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. | Q40397252 |
| | High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. | Q41735415 |
| | Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action | Q42523855 |
| | Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 |
| | High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. | Q46117208 |
| | Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 |
| | Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. | Q51022930 |
| | FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer | Q54630456 |
| | The Use of Maximum Likelihood Estimates in χ2 Tests for Goodness of Fit | Q56170499 |
| | ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma | Q74455685 |
| | Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies | Q79712479 |
| | Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors | Q81310254 |
| P433 | issue | 5 | |
| P921 | main subject | trastuzumab | Q412616 |
| | preoperative chemotherapy | Q108532530 |
| P304 | page(s) | 472-477 | |
| P577 | publication date | 2016-07-05 | |
| P1433 | published in | The Pharmacogenomics Journal | Q10534704 |
| P1476 | title | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer | |
| P478 | volume | 16 | |